secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001104659-26-028023
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive Phase 2 data: oral GLP-1 aleniglipron achieves up to 16.3% placebo-adjusted weight loss at 44 weeks
--------------------------------------------------------------------------------

- Placebo-adjusted mean weight loss 16.3% at 180 mg and 16.0% at 240 mg (p<0.0001) at 44 weeks.
- OLE study shows continued weight loss up to 16.2% at 56 weeks; no plateau observed.
- Lower 2.5 mg starting dose improves tolerability; AE-related discontinuations 2-3.4% in interim OLE / body composition studies.
- End-of-Phase 2 meeting with FDA scheduled Q2 2026; Phase 3 initiation on track for 2H 2026.
- No drug-induced liver injury, no persistent liver enzyme elevations, no QTc prolongation across >625 participants.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/0001104659-26-028023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/tm268880d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-028023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer